
    
      After being widely informed about the study and potential risks, all the patients giving
      voluntary informed consent will be randomized in a 1:1 ratio to a tDCS group (a-tDCS+
      standard treatment) or control group (placebo-simulations a-tDCS+ standard treatment).
    
  